Clinical Need | Esoguard
top of page
Guy with dog.jpg

Over 90%

of Esophageal Adenocarcinoma patients never knew they had treatable Barrett's Esophagus

 

Find Barrett's before it progresses 

EAC rates chart.png
#1 rate of increase of any cancer

Esophageal
Adenocarcinoma

has increased

over 733%

in the past 4 decades

1

Less than 10%

of high-risk GERD patients currently undergo EGD screening

2

733% Increase
EAC has increased over 733% in the past 4 decades

1

Lethal Cancer

less than 20%

5 year survival

5

Less than 10%
of EAC patients have had BE diagnosed
before EAC

4

The Unmet Clinical Need

~40%

of EAC patients were asymptomatic prior to diagnosis

3

40percent people.png
BE_in the esophagus.png

Barrett’s Esophagus screening rates are very low — even for the high-risk patients

BE screening rates.png

Multiple factors contribute to the low BE screening rate, even in high-risk patients, including limited primary physician awareness of the relationship between GERD and EAC and guidelines recommending BE screening as well as reluctance to refer patients, whose symptoms may be reasonably controlled on PPIs for an “invasive” endoscopy procedure.

eso cells.png

Since even early stage esophageal cancer carries a poor prognosis, the only opportunity to save lives is through early detection — very very early detection.

Amitabh Chak, MD, MS, FASGE

Case Western Reserve University

University Hospitals Cleveland Medical Center

​

Ready to start screening with EsoGuard?

Incorporating EsoGuard in your practice is easy. Reach out today and we'll get you started. 

References:

  1. Thuy-Van P. Hang, MD; Zachary Spiritos, MD, MPH; Anthony Gamboa, MD; Zhengjia Chen, PhD; Seth Force, MD; Steve Keilin, MD; Nabil Saba, MD; Bassel El-Rayes, MD; Qiang Cai, MD, PhD; Field Willingham, MD, MPH. THE EPIDEMIOLOGY OF ESOPHAGEAL ADENOCARCINOMA IN THE UNITED STATES. Program No. P0265. ACG 2018 Annual Scientific Meeting Abstracts. Philadelphia, Pennsylvania: American College of Gastroenterology.

  2. Deloitte Analysis, on file Lucid Dx

  3. Mikolašević, I., Bokun, T., & Filipec Kanižaj, T. (2018). Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma - where do we stand?. Croatian medical journal, 59(3), 97–99. https://doi.org/10.3325/cmj.2018.59.97

  4. Gut 2015 Jan;64(1):20-5. doi: 10.1136/gutjnl-2013-305506. Epub 2014 Apr 3.

  5. https://seer.cancer.gov/explorer/

bottom of page